Close menu




April 4th, 2024 | 08:00 CEST

+100% and more with momentum stocks: AIXTRON, BASF, Exasol

  • Software
  • Technology
  • chemicals
  • AI
Photo credits: pixabay.com

Surprise! BASF shares have gained around 25% since mid-January. And the momentum could continue. Analysts see further upside potential. But there are also skeptical voices. In contrast, the Exasol share has only just taken off. The German AI hopeful has reported orders, the share has left the downward trend, and management is buying. Analysts believe the share could perform by more than 100%. At least it is certainly not expensive. Investors in AIXTRON are still waiting for the upward trend. Speculation has stalled the share price recovery for the time being. However, there are also optimistic voices from analysts.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: AIXTRON SE NA O.N. | DE000A0WMPJ6 , BASF SE NA O.N. | DE000BASF111 , EXASOL AG NA O.N. | DE000A0LR9G9

Table of contents:


    Exasol: Share has potential and is building momentum

    While the AI high-flyer stocks NVIDIA and Super Micro Computer are consolidating, attention is turning to promising second-tier stocks. One of these is a German AI share: Exasol. Artificial intelligence has to be trained with data. This is where Exasol comes into play as a specialist in data analysis (Big Data) with its high-performance software, Espresso. With Exasol Espresso, companies - whose 200 customers include T-Mobile and Adidas - can transform vast amounts of data into faster, deeper and more cost-effective insights. After a challenging 2022 and 2023, the share has found a bottom; turnover in the share has recently risen, and it is building momentum. The Exasol share is currently trading at around EUR 2.70, and the market capitalization is around EUR 72 million. According to analysts at M.M Warburg, this is favourable, and they recommend the share as a "Buy" with a price target of EUR 6.30.

    There are good arguments for a further rise in the share price. Among other things, Exasol presented its own AI tools for data analysis in February and is expected to break even in its operating business (EBITDA) in the current year. In addition, the Management Board and Supervisory Board have bought shares in recent weeks. Sales successes were also achieved in the financial industry in the first quarter. Exasol extended existing contracts or concluded new contracts with a total of four customers from Europe and the US. The annual recurring revenue volume (ARR) is expected to be around EUR 1 million, meaning that Exasol is well on track to further increase its ARR revenue of EUR 41.7 million from 2023 and become profitable as expected. And then, of course, there is also the chance of a lucrative takeover bid from a tech giant such as Oracle or SAP in the current environment.

    AIXTRON: Customers about to jump ship?

    The AIXTRON share is still struggling to build momentum. The shock after the surprisingly weak forecast for the current year seems too deep for investors. The gentle countermovement after the share price fall was stifled by rumors that AIXTRON could lose important customers such as Wolfspeed and ON Semiconductor.

    Analysts believe that the equipment manufacturer in the semiconductor sector can achieve significantly higher share prices. Jefferies recently confirmed its "Buy" recommendation for the AIXTRON share. The Company's technology in the area of equipment for the production of silicon carbide semiconductor wafers is outstanding. Therefore, the recent speculations about market share losses should not be overestimated. Instead, analysts expect AIXTRON to achieve a market share of over 50% in this segment in the coming year**. The analysts' price target is EUR 50. The share is currently trading at just over EUR 23.

    BASF: Is the share running out of steam?

    BASF shares are currently being driven by positive momentum. The DAX-listed company's shares have risen by a strong 25% in just two months. It is now trading at EUR 54 again, marking a 52-week high. However, analysts believe that the stock may be running out of steam. According to recent analyst comments, UBS remains the most optimistic. The analysts see a fair value of the BASF share at EUR 61. While Berenberg has upgraded the share from "Hold" to "Buy", the price target of EUR 58 has almost been reached.

    Goldman Sachs rates BASF as "Neutral". The price target of EUR 53 is at the current level. Jefferies is bearish on BASF, setting a price target of EUR 43, significantly below the current level. For this reason, the chemical company's shares are only an "Underperform" for the analysts.


    Exasol's recovery is just beginning. Positive company news, share purchases by management and the leap in profitability suggest that the AI share price will continue to rise. In contrast, AIXTRON will likely need more time and positive company news to convince investors to buy in. The BASF share has been convincing in recent weeks, but the air is slowly getting thin.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on March 13th, 2025 | 07:00 CET

    Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?

    • Healthcare
    • healthtech
    • Biotechnology
    • Pharma
    • AI
    • hightech

    In 2025, the pharmaceutical market faces significant challenges, including rising costs and regulatory hurdles. In this environment, companies like NetraMark, Bayer, and Novo Nordisk could make a significant difference through innovative solutions and strategic partnerships. NetraMark, a Canadian HealthTech company, is revolutionizing clinical trials with AI technology, which could be particularly beneficial in the areas of research into active ingredients for the central nervous system and in oncology. These are currently the biggest dropouts in industry. NetraMark's technology could increase the efficiency of drug development and open up new opportunities for investors. Bayer is focusing on targeted therapies in precision oncology and has a promising drug in development that specifically targets an overarching mutation in various cancers. Novo Nordisk is cementing its reputation as an innovator in the fight against chronic obesity, particularly with its successor to the obesity drug CagriSema. The Phase III REDEFINE 2 study achieved its primary objective, although the results fell short of high expectations. A closer look is now warranted.

    Read

    Commented by Juliane Zielonka on March 12th, 2025 | 06:55 CET

    Eutelsat, MiMedia, Xiaomi – The infrastructure for the networking markets of the future, worth billions

    • Technology
    • hightech
    • Digitization
    • Satellites
    • Telecommunications

    Millions of people in emerging markets are gaining access to digital markets – a potential of great importance to investors. The French satellite communications company Eutelsat is realizing this with its satellites such as EUTELSAT KONNECT, which bring broadband internet to remote regions of Africa and the Middle East, opening up billion-dollar markets. Eutelsat is particularly active in Europe, Africa, the Middle East, and Asia. The software company MiMedia is profiting from this connectivity by providing its cloud platform on Android smartphones. The software is the small tile for your users' pictures on the smartphone, preinstalled upon activation. MiMedia achieves this implementation through partnerships such as with América Móvil, one of the largest telecommunications providers in LATAM. MiMedia, with roots in New York City, is already expanding in Africa, reaching millions of users. The Chinese tech company Xiaomi complements this with affordable hardware: With 43.1 million smartphones shipped in Q3 2024 and the new Xiaomi 15 series, it is tapping into global markets, seamlessly integrated into cloud and satellite networks. Together, they are creating an infrastructure that generates billions of dollars in revenue in high-growth regions.

    Read

    Commented by André Will-Laudien on March 11th, 2025 | 07:45 CET

    Artificial Intelligence – Fabulous profits with Xiaomi, Credissential, D-Wave, and Palantir

    • AI
    • Technology
    • Software
    • computing

    It is incredible how politics can sometimes drive markets. US President Donald Trump had broken away from Ukraine aid due to a dispute with Volodymyr Zelenskyy, and the alarm bells were immediately ringing in Europe. Defense stocks went through the roof, and EU governments scrambled to come up with new special packages to rearm NATO countries, totaling up to EUR 800 billion. The flustered chaos must have amused Vladimir Putin. However, a correction is also currently taking place in the long-hyped AI stocks. Some of the losses here are quite painful. The stock market seems to have discarded its "one-way street decree". Accumulated profits should be secured as quickly as possible. We delve deeper into the context.

    Read